|By Marketwired .||
|August 25, 2014 04:00 PM EDT||
DANBURY, CT--(Marketwired - August 25, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that Gary G. Gemignani has been appointed as the company's Chief Financial Officer, effective September 15, 2014.
"We are very pleased to have Gary join the Biodel team. His breadth of knowledge in the pharma and biotech industries, depth in financial and commercial operations, and experience in fund raising and business development will be valuable for Biodel as we move forward and establish the commercial and financing strategies for our Glucagon Emergency Management product candidate and our ultra-rapid-acting insulin programs," said Errol De Souza, president and chief executive officer of Biodel.
Mr. Gemignani has over 25 years of experience in accounting, strategic planning and financing in the life sciences industry and has held senior leadership and management roles at Novartis, Prudential Financial, Wyeth and Arthur Andersen. Mr. Gemignani was most recently with Champions Oncology where he served as Chief Financial Officer and Executive Vice President with responsibility for raising capital, investor relations and all financial operations. Prior to that, Mr. Gemignani was the Executive Vice President, Chief Operating Officer and Chief Financial Officer for Coronado Biosciences Inc., responsible for financial operations, strategic planning and business development activities. He also served as the Executive Vice President, Chief Operating Officer and Chief Financial officer of Gentium S.P.A. where he successfully developed and initiated Named Patient and Cost Recovery programs, which allowed Gentium to sell its lead product candidate on a pre-approval basis. Mr. Gemignani received a Bachelor's Degree in Accounting from St. Peter's College.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with type 1 and type 2 diabetes and our glucagon presentation that is intended to treat patients experiencing severe hypoglycemia; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a stable glucagon presentation; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a stable glucagon presentation; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject
+1 (646) 378 2942
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Mar. 27, 2017 01:15 AM EDT Reads: 1,803
Mar. 27, 2017 12:45 AM EDT Reads: 1,993
Mar. 27, 2017 12:30 AM EDT Reads: 818
Mar. 27, 2017 12:00 AM EDT Reads: 3,316
Mar. 26, 2017 11:15 PM EDT Reads: 2,867
Mar. 26, 2017 09:45 PM EDT Reads: 2,033
Mar. 26, 2017 09:45 PM EDT Reads: 7,557
Mar. 26, 2017 08:30 PM EDT Reads: 6,114
Mar. 26, 2017 07:45 PM EDT Reads: 9,582
Mar. 26, 2017 06:45 PM EDT Reads: 4,258
Mar. 26, 2017 06:30 PM EDT Reads: 2,044
Mar. 26, 2017 05:00 PM EDT Reads: 3,591
Mar. 26, 2017 05:00 PM EDT Reads: 2,135
Mar. 26, 2017 03:30 PM EDT Reads: 6,522
Mar. 26, 2017 03:15 PM EDT Reads: 2,803